2024
Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19
Cadamuro M, Lasagni A, Radu C, Calistri A, Pilan M, Valle C, Bonaffini P, Vitiello A, Toffanin S, Venturin C, Friòn-Herrera Y, Sironi S, Alessio M, Previtali G, Seghezzi M, Gianatti A, Strazzabosco M, Strain A, Campello E, Spiezia L, Palù G, Frigo A, Tosoni A, Nebuloni M, Parolin C, Sonzogni A, Simioni P, Fabris L. Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19. Journal Of Hepatology 2024, 81: 872-885. PMID: 38908437, DOI: 10.1016/j.jhep.2024.06.014.Peer-Reviewed Original ResearchConceptsIntrapulmonary vascular dilatationWorsening respiratory failureSARS-CoV-2 infectionRespiratory failureFatal COVID-19Procoagulant phenotypeSARS-CoV-2Development of intrapulmonary vascular dilatationsVascular dilatationAssociated with portal thrombosisComplication of COVID-19 infectionTissue factorWork-up of patientsHuman pulmonary microvascular endothelial cellsEndothelial cellsObliterative portal venopathyPulmonary microvascular endothelial cellsAbsence of cirrhosisFatal respiratory failureAssociated with younger ageSevere liver diseaseDevelopment of hypoxemiaPathophysiology of thrombosisPortal vein branchesSevere COVID-19
2023
Liver Transplantation in a Woman with Mahvash Disease
Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri V, Miller J, Maley W, Shah A, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler D. Liver Transplantation in a Woman with Mahvash Disease. New England Journal Of Medicine 2023, 389: 1972-1978. PMID: 37991855, DOI: 10.1056/nejmoa2303226.Peer-Reviewed Original ResearchConceptsPortal hypertensionLiver transplantationPancreatic hypertrophyMahvash diseasePancreatic α cell hyperplasiaAbsence of cirrhosisNoncirrhotic portal hypertensionΑ-cell hyperplasiaRare genetic disorderSerum glucagonDefinitive treatmentGlucagon levelsVascular diseaseMedical CenterHypertensionDiseaseAmmonia levelsHyperglucagonemiaGenetic disordersTransplantationHypertrophyGlucagonWomenHematemesisCirrhosisInterventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension
Rabiee A, Cornman-Homonoff J, Kunstman J, Garcia-Tsao G, Taddei T. Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension. Current Hepatology Reports 2023, 22: 269-275. DOI: 10.1007/s11901-023-00617-4.Peer-Reviewed Original ResearchPortal hypertensionInterventional radiologyNon-cirrhotic portal hypertensionPorto-sinusoidal vascular diseaseHepatic sinusoidal obstruction syndromeAbsence of cirrhosisPortal vein thrombosisSinusoidal obstruction syndromeBudd-Chiari syndromeSurgical treatment optionsHepatic vascular anatomyObstruction syndromeVein thrombosisSurgical treatmentTreatment optionsVascular diseaseImproved outcomesTherapeutic evaluationVascular anatomyHeterogenous groupHypertensionSyndromeDisordersOutcomesTreatment
2020
Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 530-534. PMID: 33185999, PMCID: PMC8353543, DOI: 10.1097/qai.0000000000002510.Peer-Reviewed Original ResearchConceptsSetting of HCCFIB-4Receiver-operating characteristic curveHepatocellular carcinomaHCC diagnosisPredictive valueVeterans Aging Cohort StudyEvidence of cirrhosisSetting of HIVAbsence of cirrhosisFIB-4 scoreFibrosis-4 indexIncident hepatocellular carcinomaMedical record reviewPrevalence of cirrhosisAging Cohort StudyCross-sectional studyCharacteristic curveNegative predictive valuePositive predictive valueCirrhosis statusCohort studyMechanisms of carcinogenesisRecord reviewPlatelet count
2019
Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis
Sayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia‐Tsao G. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis. Liver International 2019, 39: 2061-2065. PMID: 31365178, PMCID: PMC11340272, DOI: 10.1111/liv.14203.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusHepatitis C virusPresence of cirrhosisViral eliminationTreatment completionPlatelet countLiver fibrosisNegative HCV RNAAbsence of cirrhosisChronic HCV infectionNon-invasive scoresPlatelet count increaseChronic liver diseaseHCV infectionPortal hypertensionHCV RNAAntiviral treatmentFibrosis scoreLiver diseaseC virusFibrosis stageRetrospective analysisCirrhosisPatientsFibrosis
2017
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study. Hepatology 2017, 66: 1090-1101. PMID: 28504842, PMCID: PMC5756478, DOI: 10.1002/hep.29258.Peer-Reviewed Original ResearchConceptsSustained virologic responseOmbitasvir/paritaprevir/ritonavirParitaprevir/ritonavirTransplant recipientsLiver transplantKidney transplantAntiviral therapyLarge prospective observational cohort studyChronic hepatitis C virusLiver-kidney transplant recipientsProspective observational cohort studySolid organ transplant recipientsHepatitis C virus (HCV) treatmentBaseline total bilirubinHCV-TARGET studyPrior antiviral therapyAbsence of cirrhosisKidney transplant recipientsLiver transplant recipientsObservational cohort studyOrgan transplant recipientsC virus treatmentGlomerular filtration rateCessation of treatmentSOF/ledipasvirSurvival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLarger tumor sizeLiver diseaseHCC etiologyCurative intentNAFLD-HCCCurative treatmentTumor sizeMetastatic HCCCardiovascular diseaseHepatocellular carcinomaDecompensated liver diseaseWorse median survivalAbsence of cirrhosisSignificant survival differenceDiagnosis of HCCLess cirrhosisNAFLD groupMedian survivalWorse survivalFavorable survivalIndependent predictorsLiver cirrhosisHCC group
2014
Interventional Radiology Management of Unresectable Intrahepatic Cholangiocarcinoma
Talenfeld A, Holzwanger D, Madoff D. Interventional Radiology Management of Unresectable Intrahepatic Cholangiocarcinoma. Medical Radiology 2014, 201-223. DOI: 10.1007/978-3-642-40558-7_13.Peer-Reviewed Original ResearchInoperable intrahepatic cholangiocarcinomaTransarterial therapiesTransarterial chemoinfusionTransarterial radioembolizationIntrahepatic cholangiocarcinomaDrug-eluting bead transarterial chemoembolizationYttrium-90 transarterial radioembolizationChild A cirrhosisInterventional radiology managementUnresectable intrahepatic cholangiocarcinomaAbsence of cirrhosisMedian overall survivalLow tumor burdenBead transarterial chemoembolizationLow tumor gradeSmaller tumor sizeNormal performance statusPercutaneous ablative therapiesPercutaneous thermal ablationThermal ablationExtrahepatic diseaseConventional TACEOverall survivalPerformance statusPortal thrombus
2013
Ablation for hepatocellular carcinoma: Validating the 3-cm breakpoint.
Groeschl R, Gamblin T, Turaga K. Ablation for hepatocellular carcinoma: Validating the 3-cm breakpoint. Journal Of Clinical Oncology 2013, 31: 277-277. DOI: 10.1200/jco.2013.31.4_suppl.277.Peer-Reviewed Original ResearchDisease-specific survivalHepatocellular carcinomaTumor sizePredictive of disease-specific survivalMultivariate Cox proportional hazards modelT1 hepatocellular carcinomaEnd Results databaseAlpha-fetoprotein levelsAbsence of cirrhosisLog-rank testCox proportional hazards modelsProportional hazards modelPrognostic significanceLarger tumorsResults databaseStratify patientsAblation outcomesPoor prognosisExcellent outcomesAlpha-fetoproteinLocal ablationStudy groupTumorPatientsHazards model
2005
Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis
Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Modern Pathology 2005, 18: 1417-1423. PMID: 15920538, DOI: 10.1038/modpathol.3800449.Peer-Reviewed Original ResearchConceptsConventional hepatocellular carcinomaFibrolamellar carcinomaHepatocellular carcinomaClinicopathologic featuresOverall survivalTumor sizeMean Ki-67 indexAbsence of cirrhosisDistinct clinicopathologic featuresKi-67 indexMetastatic diseaseLymph nodesOverall mortalityDistant metastasisNonmetastatic casesPathologic featuresAggressive neoplasmNoncirrhotic liverCirrhotic liverCirrhosisKi-67Better outcomesCarcinomaProliferative activityYoung individuals
2002
Combined Hepatocellular–Cholangiocarcinoma
Tickoo S, Zee S, Obiekwe S, Xiao H, Koea J, Robiou C, Blumgart L, Jarnagin W, Ladanyi M, Klimstra D. Combined Hepatocellular–Cholangiocarcinoma. The American Journal Of Surgical Pathology 2002, 26: 989-997. PMID: 12170085, DOI: 10.1097/00000478-200208000-00003.Peer-Reviewed Original ResearchConceptsCombined hepatocellular-cholangiocarcinomaIn situ hybridizationEpithelial membrane antigenHepatocellular carcinomaHepatocellular markersMembrane antigenElevated serum alpha-fetoprotein levelsSerum alpha-fetoprotein levelAlbumin mRNASerum hepatitis BAggressive clinical courseAlpha-fetoprotein levelsPolyclonal carcinoembryonic antigenAbsence of cirrhosisPrimary liver carcinomaExpression of albumin mRNAHistomorphological spectrumResected casesClinical courseHepatocellular-cholangiocarcinomaImmunohistochemical positivityBiphenotypic differentiationClinical outcomesCytokeratin profileHepatitis B
1985
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply